Labcorp (NYSE:LH) Shares Gap Down – Here’s Why

Posted by Geri Gentry on Jul 14th, 2026

Labcorp Holdings Inc. (NYSE:LH – Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $276.68, but opened at $262.11. Labcorp shares last traded at $275.99, with a volume of 59,497 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LH. Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Robert W. Baird lifted their price target on shares of Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a research report on Monday. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Bank of America raised their price objective on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $314.40.

Read Our Latest Report on LH

Labcorp Trading Down 0.4%

The firm has a 50-day moving average of $264.47 and a two-hundred day moving average of $267.33. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $22.60 billion, a P/E ratio of 24.41, a P/E/G ratio of 1.94 and a beta of 0.89.

Labcorp (NYSE:LH – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the previous year, the company posted $3.84 EPS. Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio is presently 25.51%.

Insider Transactions at Labcorp

In related news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the sale, the executive vice president owned 3,813 shares in the company, valued at $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,991 shares of company stock worth $1,796,696 over the last ninety days. 0.84% of the stock is owned by insiders.

Hedge Funds Weigh In On Labcorp

A number of hedge funds have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in Labcorp during the third quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the 4th quarter worth about $26,000. Hilton Head Capital Partners LLC bought a new position in shares of Labcorp in the 4th quarter worth about $27,000. Eagle Bay Advisors LLC bought a new position in shares of Labcorp in the 4th quarter worth about $29,000. Finally, DV Equities LLC acquired a new position in shares of Labcorp in the 4th quarter valued at about $29,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Company Profile

(Get Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.